SNAPSS ASSIGNMENT COMPLETED, Study Guides, Projects, Research of Nursing

COMPLETED SNAPPS ASSIGNMENT FOR NR 576

Typology: Study Guides, Projects, Research

2023/2024

Uploaded on 06/07/2024

parneet-kaur-19
parneet-kaur-19 🇺🇸

1 / 3

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
SNAPPS WRITTEN ASSIGNMENT TEMPLATE
What is the self-directed learning issue that was identified in your oral presentation?
Research the self-directed learning issue and provide a summary of your findings which is fully
supported by appropriate, scholarly, EBM references.
The self-directed learning issue identified in the oral presentation on allergic conjunctivitis was
the need to gain a deeper understanding of the latest advancements and evidence-based
approaches in the management of the condition. Specifically, the presentation highlighted the
importance of self-directed learning to stay updated on treatment modalities, environmental
control measures, emerging therapies, allergen immunotherapy, and patient education strategies
for allergic conjunctivitis. This self-directed learning issue aimed to enhance knowledge and
skills in providing comprehensive care to patients with allergic conjunctivitis and optimizing
patient outcomes.
[Write your self-directed learning topic that was identified in your presentation here]
pf3

Partial preview of the text

Download SNAPSS ASSIGNMENT COMPLETED and more Study Guides, Projects, Research Nursing in PDF only on Docsity!

SNAPPS WRITTEN ASSIGNMENT TEMPLATE

What is the self-directed learning issue that was identified in your oral presentation?

Research the self-directed learning issue and provide a summary of your findings which is fully

supported by appropriate, scholarly, EBM references.

The self-directed learning issue identified in the oral presentation on allergic conjunctivitis was

the need to gain a deeper understanding of the latest advancements and evidence-based

approaches in the management of the condition. Specifically, the presentation highlighted the

importance of self-directed learning to stay updated on treatment modalities, environmental

control measures, emerging therapies, allergen immunotherapy, and patient education strategies

for allergic conjunctivitis. This self-directed learning issue aimed to enhance knowledge and

skills in providing comprehensive care to patients with allergic conjunctivitis and optimizing

patient outcomes.

[Write your self-directed learning topic that was identified in your presentation here]

After conducting a comprehensive search, here is a summary of the findings:

  • Novel Pharmacological Agents: Recent studies have investigated the efficacy of novel pharmacological agents in the management of allergic conjunctivitis. These agents include dual-acting antihistamine and mast cell stabilizer medications, such as olopatadine and ketotifen fumarate. Research suggests that these agents offer improved symptom relief and may have a longer duration of action compared to traditional antihistamines alone (Torkildsen, 2018).
  • Immunomodulators: Immunomodulatory agents, such as calcineurin inhibitors (e.g., tacrolimus) and phosphodiesterase inhibitors (e.g., cyclosporine A), have been investigated for their potential role in managing allergic conjunctivitis. These agents work by suppressing immune responses and inhibiting the release of inflammatory cytokines, offering an alternative treatment approach for patients with refractory disease (Leung et al., 2019). In summary, emerging therapies for allergic conjunctivitis, including novel pharmacological agents, biologics, gene therapies, and immunomodulators, offer promising avenues for improving symptom control and quality of life in patients with allergic conjunctivitis. Further research and clinical trials are warranted to validate the efficacy and safety of these emerging treatments in real-world settings.
  • Biologics: Biologic agents targeting specific inflammatory mediators, such as immunoglobulin E (IgE) and interleukin- (IL-4), have shown promise in the treatment of allergic conjunctivitis. Monoclonal antibodies, such as omalizumab and dupilumab, have demonstrated efficacy in reducing ocular symptoms and improving quality of life in patients with severe allergic conjunctivitis refractory to conventional therapies (Ibrahim et al., 2019). In summary, emerging therapies for allergic conjunctivitis, including novel pharmacological agents, biologics, gene therapies, and immunomodulators, offer promising avenues for improving symptom control and quality of life in patients with allergic conjunctivitis. Further research and clinical trials are warranted to validate the efficacy and safety of these emerging treatments in real-world settings.